Clinical practice guideline: hoarseness (dysphonia).

GUIDELINE TITLE
Clinical practice guideline: hoarseness (dysphonia).

BIBLIOGRAPHIC SOURCE(S)
Schwartz S, Cohen S, Dailey S, Rosenfeld R, Deutsch E, Gillespie B, Granieri E, Hapner E, Kimball E, Krouse H, McMurray S, Medina S, O'Brien K, Ouellette D, Messinger-Rapport B, Stachler R, Strode S, Thompson D, Stemple J, Willging P, Cowley T, McCoy, Bernad P, Patel M. Clinical practice guideline: hoarseness (dysphonia). Otolaryngol Head Neck Surg 2009 Sep;141(3S2):S1-S31. [21 references]

GUIDELINE STATUS
This is the current release of the guideline.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory information has been released.

August 3, 2009 – Onabotulinum toxin A (Botox/Botox Cosmetic), Abobotulinum toxin A (Dysport) and Rimabotulinum toxin B (Myobloc): The U.S. Food and Drug Administration (FDA) notified healthcare professionals of changes to the established drug names for Botox/Botox Cosmetic, Dysport and Myobloc to reinforce individual potencies and prevent medication errors, and provided recommendations for healthcare professionals to consider, plus information for patients, family members, and caregivers.

open here to see rhe full-text:
Clinical practice guideline: hoarseness (dysphonia).